Enrollment is complete for PolarisDMD!

We are excited to announce that enrollment is now complete for the Phase 3 PolarisDMD trial of edasalonexent in Duchenne muscular dystrophy. Thank you to those affected by Duchenne, their families, patient advocacy organizations, and our investigators and clinical trial site staff for your support throughout enrollment. Top-line results for this study are expected in Q4 2020 and are anticipated to support a New Drug Application (NDA) filing in 2021.

Thank you FROM THE CATABASIS TEAM!

Thank you to the incredible Duchenne community, which often feels like an extension of our own family. The unparalleled support by the community, families, and trial sites has led to a wonderful accomplishment, and we are extremely grateful. We are in this together, so thank you very much for your continued trust in Catabasis.

Maria Mancini
Vice President,
Clinical Operations

Thank you to the families who enrolled their sons in our MoveDMD trial who have made the Phase 3 trial possible. You have paved the way for us to be where we are today. It is an honor to fight alongside the Duchenne community every day.

Liz Thaler
Manager,
Clinical Operations

The Phase 3 PolarisDMD trial was a community effort, including families, site personnel, investigators, advocacy groups, and our Catabasis colleagues. Thank you for all that you’ve done!

Joanne Donovan
Chief Medical Officer

Our sincerest thank you to the clinical site staff for all of their hard work and success in completing enrollment for the PolarisDMD trial. Their dedication to the Duchenne community and families is incredible. We are honored to have them as an extension of the Catabasis team.

Leslie Cowen
Manager,
Clinical Operations
The information provided here is for parents and caregivers of boys with Duchenne muscular dystrophy. Edasalonexent is an investigational drug that is not yet approved in any territory.

Stay in touch!
Join our mailing list: http://www.catabasis.com/patients-families/for-further-information.php
Follow us on social media: @CatabasisPharma.

The information provided here is for parents and caregivers of boys with Duchenne muscular dystrophy. Edasalonexent is an investigational drug that is not yet approved in any territory.

What's next for PolarisDMD?

The Phase 3 PolarisDMD trial is a 1-year trial. After 52 weeks in the trial are complete, boys have the option to transition to GalaxyDMD, our open-label extension study, where everyone (including eligible siblings) can receive edasalonexent. The GalaxyDMD study is focused on long-term safety of edasalonexent, with site visits every 6 months.

Top-line results from PolarisDMD are expected in Q4 2020. This trial is intended to support an NDA filing in 2021.

Making Community Connections

Catabasis will also be attending each of the following upcoming events and we are looking forward to connecting with the Duchenne community both in the US and the UK!

Duchenne UK Patient and Caregiver Information Day—September 28th in Manchester, UK. This one-day event will ensure parents receive the most up-to-date information on caring for their child. Find out more at duchenneuk.org/patientinformationday

PPMD End Duchenne Tour—October 26th in Memphis, TN. To learn about PPMD’s effort to reach every single family facing a Duchenne diagnosis in the US, visit www.parentprojectmd.org/get-involved/attend-events/end-duchenne-tour

The CureDuchenne Futures Conference—October 11th in Anaheim, CA. Learn more about this comprehensive 2-day event at cureduchenne.org/event/cureduchenne-futures/

Cure Rare Disease Gala—October 24th in Boston, MA. This annual event benefits the Cure Rare Disease mission to develop customized therapeutics for rare, genetic diseases. For information or to register, visit cureraredisease.org/2019-annual-gala

About Edasalonexent

In Duchenne, the loss of dystrophin leads to chronic activation of NF-kB, which is a key driver of skeletal and cardiac muscle disease progression. By inhibiting NF-kB, edasalonexent has the potential to decrease inflammation and fibrosis, promote muscle regeneration, and slow disease progression. Edasalonexent is being developed as a potential stand-alone therapy and may also have the potential to be co-administered with dystrophin-targeted therapies.